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used to select the sample were unclear. An overall sample of 67,800 individuals was contacted. The individuals were then allocated to receive either ultrasound screening for AAA (n=33, 839) or no such screening (n=33,961) . No other details of the patients' characteristics were provided.
Study design
This was a prospective, multi-centre, randomised clinical trial that was conducted at four centres in the UK. The method of randomisation was not described. Few details of the follow-up were reported. The length of follow-up was 4 years. It was unclear whether some patients were lost to the follow-up assessment.
Analysis of effectiveness
The analysis of the clinical study appears to have been conducted on an intention to treat basis. Patients with less than 4 years of follow-up, and those who died from other causes than those related to AAA, were treated as censored observations. The outcome measures used in the analysis were the number of AAA-related deaths and survival time.
The baseline comparability of the study groups was not discussed.
Effectiveness results
The number of AAA-related deaths was 58 in the intervention group and 105 in the control group. 
Clinical conclusions
The effectiveness study showed that the screening strategy for AAA led to a substantial reduction in the number of AAA-related deaths. However, over the 4-year period, the survival time between screening and no screening was quite comparable.
Methods used to derive estimates of effectiveness
The authors made some assumptions to extrapolate the 4-year clinical results to a 10-year timeframe.
Estimates of effectiveness and key assumptions
It was assumed that: the benefits of screening were restricted to mortality related to AAA; those for whom such deaths were presented were subjected to the same "other cause" mortality as the general population; and in years 5 to 10, the absolute risk reduction in such mortality accumulated at only half the rate of that observed in years 2 to 4.
Measure of benefits used in the economic analysis
The summary benefit measure used was survival time. This was derived directly from the effectiveness analysis. An annual rate of 1.5% was used in the base-case analysis.
Direct costs
Discounting was applied as the costs were incurred during a timeframe of longer than 2 years. An annual rate of 6% was applied. The unit costs were presented separately from the quantities of resources used for most items. The health
